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Sir,
We appreciate the comments of Drs Hagmar and
To ¨rnqvist (2003) on our article assessing dietary acrylamide
and cancer risk (Mucci et al, 2003). We take this opportunity
to clarify some issues and to present data from additional
analyses.
We undertook the original investigation in light of claims by the
Swedish National Food Administration that acrylamide in foods
could have global impacts on cancer incidence rates. In spite of the
potential limitations of the study design, our data are reassuring
that acrylamide seems unlikely to be responsible for a major
fraction of these cancers. As stated in our discussion, however,
additional data are needed before a global assessment of any risks
of dietary acrylamide can be undertaken in relation to other cancer
sites and neurological diseases.
The reliance on toxicological risk assessment models employed
by Hagmar and To ¨rnqvist may be questionable. Estimates of
human cancer risk were extrapolated from animal models, given
doses of acrylamide several fold higher than those to which
humans are exposed (International Agency for Research on Cancer
(IARC), 1994). We think that animal data must be generalized to
humans with caution. This sentiment is reflected by IARC (2002)
who considers an agent as definitely carcinogenic to humans when
there is sufficient evidence from studies in humans (i.e.
epidemiological evidence) and only ‘exceptionally’ in other
situations.
The authors present evidence from power analyses on the
substantial sample size needed to detect an effect of acrylamide on
human cancer risk. Notwithstanding the limitations of the risk
assessment models, the authors determined an expected relative
risk of 1.05 for the highest vs lowest dose. An effect estimate of this
size is almost impossible to determine in any observational study.
Indeed, not even a randomised clinical trial would have the power
to detect this effect. The scientific methods to study such a small
effect currently do not exist, and beg the question of how to best
proceed to address the question of acrylamide and cancer. In
addition, we must ask whether a relative risk of this size warranted
the public health alarm that was generated when the findings of
acrylamide in food were first announced.
Additional data
Since our study was published, new data have come available
on acrylamide content in additional food items. In parti-
cular, acrylamide has been detected in coffee. Although the
range of exposure (B8mgkg
1) is lower than other items,
coffee may account for a substantial proportion of total dose
because of the frequency of consumption. We present updated
data from the original case–control study, using a similar
methodology.
Coffee consumption was common in this Swedish population,
with 23.5% of controls consuming four or more cups of coffee per
day. The daily mean (standard error) dietary acrylamide dose (mg)
increased with the addition of coffee data: 34.0 (0.6) for controls,
34.8 (0.6) for colorectal, 36.8 (1.0) for bladder, and 34.5 (1.4) for
kidney cancers. Crisp breads (28%) and coffee intake (20%)
contributed to the largest sources of acrylamide in the diet among
controls (Figure 1). Quartiles of dietary acrylamide dose were
calculated based on the distribution among the controls. Adjusting
for potential confounders, the risk of colorectal (Figure 2A) and
kidney cancers (Figure 2C) decreased with increasing acrylamide
dose. The apparent protective effect of acrylamide parallels the
lower risk associated in this study with crisp breads and for coffee,
a finding consistently observed in the literature (Ekbom, 1999).
The relative risk estimate of acrylamide and bladder cancer was
essentially null (Figure 2B).
Expanding the range of exposure and achieving a more complete
estimate of acrylamide intake, there remains no evidence of an
excess risk of the three studied cancers in relation to acrylamide,
and provides further reassurance that acrylamide in diet does not
appear to be responsible for a major fraction of these three
cancers.
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Figure 1 Major sources of acrylamide in investigated foods in the
Swedish diet, among controls.
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Figure 2 Quartiles of daily dietary acrylamide dose and risk of cancer of
the (A) large bowel, (B) bladder and (C) kidney.
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